References

Assessing diagnostic performance

10.1056/evidra2300232 · 2024 · External reference

Food allergy: a practice parameter

2006 · External reference

Elimination diets in Eczema—A cautionary tale

10.1016/j.jaip.2015.10.009 · 2016 · External reference

Evolving interpretation of screening and diagnostic tests in allergy

10.1016/j.jaip.2021.05.018 · 2021 · External reference

Unresolved reference

1989 · External reference

Predictive values of component-specific IgE for the outcome of peanut and hazelnut food challenges in children

10.1111/all.12530 · 2015 · External reference

IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper

10.1016/j.waojou.2019.100080 · 2020 · External reference

In vivo methods for the study and diagnosis of allergy

2020 · External reference

Diagnosing peanut allergy with skin prick and specific IgE testing

10.1016/j.jaci.2005.02.038 · 2005 · External reference

Wheat allergy: a double-blind, placebo-controlled study in adults

10.1016/j.jaci.2005.10.014 · 2006 · External reference

EAACI guidelines on the diagnosis of IgE-mediated food allergy

10.1111/all.15902 · 2023 · External reference

Improving diagnostic accuracy in food allergy

10.1016/j.jaip.2020.09.037 · 2021 · External reference

Laboratory tests for allergic and immunodeficiency diseases

2020 · External reference

Systematic review and meta-analyses on the accuracy of diagnostic tests for IgE-mediated food allergy

10.1111/all.15939 · 2024 · External reference

Allergen-specific IgE is a stronger predictor of remission following peanut oral immunotherapy than age in children aged 1-10 years

10.1111/all.16451 · 2025 · External reference

Clinical significance of immunoglobulin E

2020 · External reference

EAACI molecular allergology user's guide 2.0

2023 · External reference

Diagnostic accuracy, risk assessment, and cost-effectiveness of component-resolved diagnostics for food allergy: a systematic review

10.1111/all.13399 · 2018 · External reference

Novel bead-based epitope assay is a sensitive and reliable tool for profiling epitope-specific antibody repertoire in food allergy

10.1038/s41598-019-54868-7 · 2019 · External reference

Accurate and reproducible diagnosis of peanut allergy using epitope mapping

10.1111/all.14905 · 2021 · External reference

Accuracy of bead-based epitope assay testing for peanut allergy diagnosis: real-world pediatric population study

10.1016/j.anai.2025.02.010 · 2025 · External reference

Predicting probability of tolerating discrete amounts of peanut protein in allergic children using epitope-specific IgE antibody profiling

10.1111/all.15477 · 2022 · External reference

The basophil activation test is the Most accurate test in predicting allergic reactions to baked and fresh cow's milk during oral food challenges

10.1111/all.16675 · 2025 · External reference

Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice

10.1111/all.14747 · 2021 · External reference

Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy

10.1016/j.jaci.2007.11.026 · 2008 · External reference

Influence of omalizumab on allergen-specific IgE in patients with adult asthma

10.1159/000442668 · 2015 · External reference

Unresolved reference

External reference

Effect of benralizumab on inflammation in skin after intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis

2024 · External reference

Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: a real-life multicentre study (BIONIGE)

10.1002/clt2.12143 · 2022 · External reference

Extrafollicular IgD+ B cells generate IgE antibody secreting cells in the nasal mucosa

10.1038/s41385-021-00410-w · 2021 · External reference

Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients

2022 · External reference

Tralokinumab treatment in adult atopic dermatitis patients: 28-week evaluation of clinical effectiveness, safety, serum proteins and total IgE levels

10.1111/all.16414 · 2024 · External reference

Diagnostics of allergic rhinitis under dupilumab therapy

10.1007/s00405-024-08700-2 · 2024 · External reference

Food allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis

10.1016/j.anai.2025.07.023 · 2025 · External reference

Efficacy and safety of dupilumab in children with peanut allergy: a multicenter, open-label, phase II study

10.1111/all.16404 · 2025 · External reference

Tezepelumab in patients with allergic and eosinophilic asthma

10.1111/all.15986 · 2023 · External reference

Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial

10.1016/j.jaci.2022.08.029 · 2023 · External reference

Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

10.1111/cts.13005 · 2021 · External reference

Pharmacodynamic analysis of BTK inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib

10.1158/1078-0432.ccr-19-3505 · 2020 · External reference

No clinically meaningful impact of remibrutinib on immunoglobulin levels or infections in chronic spontaneous urticaria

10.1016/j.anai.2024.08.317 · 2024 · External reference

Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks

10.1016/j.jaci.2023.10.007 · 2024 · External reference